论文部分内容阅读
目的探讨舒利迭在中重度慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)治疗中的应用效果及对患者治疗依从性的影响。方法选择2014年1月—2015年1月期间本院收治的96例中重度COPD患者为研究对象,按照就诊先后顺序被随机分为两组。对照组48例予常规内科治疗,观察组48例加用舒利迭吸入治疗(沙美特罗50μg,丙酸氟替卡松250μg),2次/d。两组疗程均为3个月,对比临床疗效及患者治疗依从性,计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果治疗后观察组FVC、FEV1、FEV1/FVC[(3.36±1.07)、(1.96±0.24)L、(70.42±11.06)%]与治疗前和对照组比较[(2.49±0.88)、(1.32±0.29)L、(51.76±8.23)%、(2.72±1.13)、(1.38±0.31)L、(54.38±7.95)%]均明显改善,对比差异均有统计学意义(均P<0.05)。治疗后观察组患者Pa O2较治疗前和对照组明显升高,Pa CO2较治疗前和对照组明显降低[(74.83±5.16)、(62.47±4.28)、(65.32±4.71)、(41.26±3.49)、(53.87±3.58)、(50.69±3.76)mm Hg(1 mm Hg=0.133 k Pa)],对比差异均有统计学意义(均P<0.05)。观察组治疗依从率为97.92%,显著高于对照组的79.17%,对比差异均有统计学意义(均P<0.05)。结论舒利迭用于中重度COPD治疗能有效改善患者的肺功能及血气指标,并能提高患者治疗依从性,极具临床应用价值。
Objective To investigate the effect of seretide on the treatment of moderate and severe chronic obstructive pulmonary disease (COPD) and its effect on the compliance of patients. Methods A total of 96 patients with moderate-to-severe COPD admitted to our hospital from January 2014 to January 2015 were selected and randomly divided into two groups according to the order of their visits. 48 cases in the control group were given routine medical treatment, 48 cases in the observation group were treated with seretide inhalation (salmeterol 50 μg, fluticasone propionate 250 μg) twice a day. Two courses of treatment were 3 months, compared with clinical efficacy and patient compliance, measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results After treatment, FVC, FEV1, FEV1 / FVC in the observation group were significantly higher than those in the control group [(2.49 ± 0.88), (1.32 ± 1.88), (1.96 ± 0.24) L, 0.29) L, (51.76 ± 8.23)%, (2.72 ± 1.13), (1.38 ± 0.31) L, (54.38 ± 7.95)%], all of which were statistically significant (all P <0.05). After treatment Pa Pa O2 in the observation group was significantly higher than that before treatment and in the control group, Pa CO2 was significantly lower than before treatment and in the control group [(74.83 ± 5.16), (62.47 ± 4.28), (65.32 ± 4.71), (41.26 ± 3.49 ), (53.87 ± 3.58) and (50.69 ± 3.76) mm Hg (1 mm Hg = 0.133 kPa), respectively. There was significant difference between the two groups (all P <0.05). The compliance rate of the observation group was 97.92%, which was significantly higher than that of the control group (79.17%), the differences were statistically significant (all P <0.05). Conclusion Seretide for the treatment of moderate and severe COPD can effectively improve the patient’s lung function and blood gas indicators, and can improve the patient’s compliance with treatment, great clinical value.